BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33413085)

  • 1. H2V: a database of human genes and proteins that respond to SARS-CoV-2, SARS-CoV, and MERS-CoV infection.
    Zhou N; Bao J; Ning Y
    BMC Bioinformatics; 2021 Jan; 22(1):18. PubMed ID: 33413085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transcriptomic profiling of SARS-CoV-2 compared to SARS, MERS, EBOV, and H1N1.
    Alsamman AM; Zayed H
    PLoS One; 2020; 15(12):e0243270. PubMed ID: 33301474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lethal internal face of the coronaviruses: Kidney tropism of the SARS, MERS, and COVID19 viruses.
    Motavalli R; Abdelbasset WK; Rahman HS; Achmad MH; Sergeevna NK; Zekiy AO; Adili A; Khiavi FM; Marofi F; Yousefi M; Ghoreishizadeh S; Shomali N; Etemadi J; Jarahian M
    IUBMB Life; 2021 Aug; 73(8):1005-1015. PubMed ID: 34118117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.
    Krishnamoorthy P; Raj AS; Roy S; Kumar NS; Kumar H
    Comput Biol Med; 2021 Jan; 128():104123. PubMed ID: 33260034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection.
    Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH
    Front Immunol; 2020; 11():1022. PubMed ID: 32574260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection.
    Iwata-Yoshikawa N; Okamura T; Shimizu Y; Hasegawa H; Takeda M; Nagata N
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30626688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.
    Molaei S; Dadkhah M; Asghariazar V; Karami C; Safarzadeh E
    Int Immunopharmacol; 2021 Mar; 92():107051. PubMed ID: 33429331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.
    Rockx B; Kuiken T; Herfst S; Bestebroer T; Lamers MM; Oude Munnink BB; de Meulder D; van Amerongen G; van den Brand J; Okba NMA; Schipper D; van Run P; Leijten L; Sikkema R; Verschoor E; Verstrepen B; Bogers W; Langermans J; Drosten C; Fentener van Vlissingen M; Fouchier R; de Swart R; Koopmans M; Haagmans BL
    Science; 2020 May; 368(6494):1012-1015. PubMed ID: 32303590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
    Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV.
    Liu J; Zheng X; Tong Q; Li W; Wang B; Sutter K; Trilling M; Lu M; Dittmer U; Yang D
    J Med Virol; 2020 May; 92(5):491-494. PubMed ID: 32056249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The analysis on the human protein domain targets and host-like interacting motifs for the MERS-CoV and SARS-CoV/CoV-2 infers the molecular mimicry of coronavirus.
    Martínez YA; Guo X; Portales-Pérez DP; Rivera G; Castañeda-Delgado JE; García-Pérez CA; Enciso-Moreno JA; Lara-Ramírez EE
    PLoS One; 2021; 16(2):e0246901. PubMed ID: 33596252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
    Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
    J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection.
    Delgado-Roche L; Mesta F
    Arch Med Res; 2020 Jul; 51(5):384-387. PubMed ID: 32402576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century.
    da Costa VG; Moreli ML; Saivish MV
    Arch Virol; 2020 Jul; 165(7):1517-1526. PubMed ID: 32322993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS.
    Li H; Hu Y; Tang H; Li S; Ding H; Zhai S; Zhao R
    Am J Chin Med; 2020; 48(7):1539-1552. PubMed ID: 33202150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic landscape of SARS-CoV-2- and MERS-CoV-infected primary human renal epithelial cells.
    Kohli A; Sauerhering L; Fehling SK; Klann K; Geiger H; Becker S; Koch B; Baer PC; Strecker T; Münch C
    Life Sci Alliance; 2022 May; 5(5):. PubMed ID: 35110370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.
    Kim KS; Ejima K; Iwanami S; Fujita Y; Ohashi H; Koizumi Y; Asai Y; Nakaoka S; Watashi K; Aihara K; Thompson RN; Ke R; Perelson AS; Iwami S
    PLoS Biol; 2021 Mar; 19(3):e3001128. PubMed ID: 33750978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.